ArticleBMC cancer2025
Comprehensive analysis of BIRC5: from pan-cancer analysis to experimental validation.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBaculoviral inhibitor of apoptosis protein repeat-containing protein 5 (BIRC5), also known as survivin, belongs to the inhibitor of apoptosis proteins (IAP) family and serves as a key regulator of cellular survival and programmed cell death. Current research has demonstrated that BIRC5 exhibits high expression levels in many cancers. Furthermore, its overexpression significantly correlates with poor clinical outcomes and contributes to tumor progression and metastasis.
methodsWe utilized TCGAplot R package (v8.0.0), Sangerbox3.0, GEPIA2, cBioPortal, UALCAN, TISIDB, BioGRID, and single-cell RNA sequencing (scRNA-seq) data to decipher the close association of BIRC5 with tumor occurrence and development as well as its involvement in gene mutations, methylation patterns, immune infiltration levels, functional aspects, and prognosis outcomes. Additionally, the expression of BIRC5 was assessed through western blot analysis following siRNA transfection in Lung adenocarcinoma (LUAD) cell lines. CCK-8 and Colony Formation Assays quantified proliferative changes in H1299 and A549 cells following BIRC5 downregulation.
resultsPan-cancer analysis has demonstrated that BIRC5 expression is frequently upregulated in various tumor types. The dysregulation of BIRC5 has been strongly linked to poor clinical prognosis across various cancers. Moreover, alterations in BIRC5 gene have been observed in different tumors. Compared with normal tissues, the BIRC5 promoter region shows abnormal methylation levels in most cancer tissues. Additionally, BIRC5 is implicated in immune infiltration and immune cell composition with the tumor microenvironment (TME), suggesting its potential role in shaping the immunological landscape of cancer. The study also elucidates the correlation between BIRC5 and immune checkpoint (ICP) expression. Furthermore, scRNA-seq findings underscore the pivotal role played by BIRC5 in regulating a wide range of biological behaviors such as cell cycle progression, DNA damage, DNA repair response, proliferation, and invasion within tumors. Experimental evidence further confirms that knockdown of BIRC5 effectively inhibits LUAD proliferation.
conclusionOur research systematically highlighted the profound association between BIRC5 expression and various clinical characteristics, survival, mutation patterns, and TME in many cancers. These analyses yield valuable perspectives on BIRC5’s function across different cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.